Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 630Triple Negative Breast Neoplasms 166Ovarian Neoplasms 103Carcinoma, Non-Small-Cell Lung 100Neoplasm Metastasis 76Colorectal Neoplasms 64Melanoma 61Stomach Neoplasms 60Neoplasms 56Pancreatic Neoplasms 55Squamous Cell Carcinoma of Head and Neck 50Prostatic Neoplasms 48Endometrial Neoplasms 48Lung Neoplasms 47Uterine Cervical Neoplasms 36Carcinoma, Renal Cell 35Sarcoma 33Head and Neck Neoplasms 33Esophageal Neoplasms 32Breast Neoplasms, Male 29Urinary Bladder Neoplasms 26Small Cell Lung Carcinoma 26Colonic Neoplasms 26Carcinoma, Transitional Cell 23Carcinoma, Ovarian Epithelial 21Lymphoma 18Brain Neoplasms 18Kidney Neoplasms 17Carcinoma, Hepatocellular 17Liver Neoplasms 15

Interventions

pembrolizumab 1eribulin 1Taxes 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Inoperable Locally Advanced HER2-Negative Breast Cancer × Breast × Clear all
NCT06942234 2025-09-17

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Recruiting
180 enrolled
Breast

Inoperable Locally Advanced HER2-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡